N※N

Market close: Healthcare giants drive positive day on NZ sharemarket

Healthcare Giants Propel NZ Sharemarket to Positive Close Amid Global Optimism

In a buoyant session on the New Zealand sharemarket, healthcare heavyweights emerged as the primary catalysts for gains, steering the benchmark S&P/NZX 50 Index to a solid finish. The index climbed 0.6 percent, or 72.45 points, to settle at 12,058.32, marking a welcome rebound after recent volatility. This uptick was largely fueled by strong performances from key players in the healthcare sector, which benefited from favorable global sentiment and robust corporate earnings reports. As investors navigated a landscape influenced by international economic cues, the local market demonstrated resilience, with trading volumes reflecting heightened activity across several blue-chip stocks.

Leading the charge was Fisher & Paykel Healthcare, a cornerstone of New Zealand's export-driven economy and a global leader in respiratory care products. The company's shares surged 2.3 percent to close at $29.50, adding significant momentum to the overall index. This rise can be attributed to renewed investor confidence in the firm's growth prospects, particularly in light of ongoing demand for its innovative medical devices amid a post-pandemic recovery in healthcare spending worldwide. Fisher & Paykel, known for its humidifiers, masks, and ventilators, has been expanding its footprint in key markets like the United States and Europe, where aging populations and advancements in telemedicine are driving sustained demand. Analysts point to the company's recent quarterly results, which showcased double-digit revenue growth, as a key factor bolstering share prices. This performance not only lifted the healthcare sector but also underscored New Zealand's prowess in high-tech manufacturing, contributing to the nation's export narrative.

Complementing Fisher & Paykel's gains was EBOS Group, another healthcare titan with a diversified portfolio spanning pharmaceuticals, medical supplies, and animal health products. EBOS shares advanced 1.8 percent to $36.20, reflecting positive market reactions to its strategic acquisitions and resilient supply chain operations. The company, which operates across Australia and New Zealand, has been navigating global supply disruptions effectively, ensuring steady distribution of essential health products. Investors appear optimistic about EBOS's ability to capitalize on emerging trends such as personalized medicine and e-commerce in pharmaceuticals, which could further enhance its market position. Together, these healthcare giants accounted for a substantial portion of the NZX 50's upward movement, highlighting the sector's defensive qualities in uncertain times—attributes that make it attractive during periods of economic flux.

Beyond healthcare, the market saw mixed but generally positive contributions from other sectors. In the energy space, Meridian Energy, New Zealand's largest electricity generator, posted a modest gain of 0.9 percent to $6.45. This uptick comes amid discussions around renewable energy transitions, with Meridian benefiting from government initiatives aimed at achieving carbon neutrality. The company's focus on hydro and wind power positions it well in a global push towards sustainable energy sources, potentially shielding it from volatility in fossil fuel markets. Similarly, Contact Energy rose 1.2 percent to $8.60, buoyed by stable demand for electricity and ongoing investments in geothermal projects. These gains in utilities provided a counterbalance to some softer performances elsewhere, reinforcing the market's overall stability.

However, not all sectors shared in the positivity. The technology segment experienced some pressure, with companies like Serko, a travel booking software provider, dipping 1.5 percent to $3.25. This decline may stem from lingering concerns over travel industry recovery, as international borders and consumer confidence continue to fluctuate. In retail, The Warehouse Group fell 0.8 percent to $1.25, possibly reflecting broader economic headwinds such as inflation and reduced discretionary spending. Despite these pockets of weakness, the market's breadth remained encouraging, with 78 stocks advancing compared to 42 decliners, and trading value reaching approximately $120 million—a figure indicative of active participation from both domestic and international investors.

The positive close on the NZX aligns with broader global trends, where Wall Street's major indices also ended higher overnight, driven by tech sector rebounds and easing inflation fears. In the United States, the Dow Jones Industrial Average gained 0.4 percent, while the S&P 500 and Nasdaq Composite rose 0.6 percent and 0.8 percent, respectively. This optimism spilled over into Asian markets, with Australia's ASX 200 climbing 0.7 percent, providing a supportive backdrop for New Zealand equities. Local traders noted that reduced concerns over interest rate hikes from central banks, including the Reserve Bank of New Zealand, contributed to the upbeat mood. The RBNZ's recent signals of a potential pause in monetary tightening have alleviated some pressure on borrowing costs, encouraging investment in growth-oriented stocks like those in healthcare.

Market commentators offered varied insights into the day's dynamics. Grant Davies, an investment adviser at Hamilton Hindin Greene, emphasized the role of healthcare stocks in providing stability. "In a market where volatility is the norm, companies like Fisher & Paykel and EBOS offer a safe haven due to their essential services and global reach," Davies remarked. He added that the sector's performance could signal broader economic recovery, as healthcare spending often correlates with consumer confidence and demographic shifts. Similarly, Sam Trethewey from Milford Asset Management highlighted the interplay between local and international factors. "We're seeing a ripple effect from positive US data, which is boosting export-exposed firms here in New Zealand," Trethewey noted, pointing to the kiwi dollar's slight appreciation against the US dollar as an additional tailwind.

Looking ahead, investors will be closely monitoring upcoming economic indicators, including New Zealand's latest GDP figures and inflation data, which could influence the RBNZ's next moves. The healthcare sector's momentum may persist if global health trends continue to favor innovation and expansion. For instance, Fisher & Paykel's ongoing research into advanced respiratory technologies could yield new product launches, further enhancing shareholder value. EBOS, meanwhile, is poised to benefit from its acquisitions in the veterinary space, tapping into the growing pet care market.

In summary, the NZ sharemarket's positive close was a testament to the strength of its healthcare leaders, who not only drove index gains but also exemplified the resilience of New Zealand's economy. With a total of 1.2 billion shares traded across the session, the market demonstrated robust liquidity and investor engagement. As global uncertainties linger—ranging from geopolitical tensions to supply chain issues—the defensive appeal of sectors like healthcare could continue to underpin market performance. This session serves as a reminder of the interconnectedness of local markets with worldwide trends, where strategic sectors can turn potential headwinds into opportunities for growth. Investors remain cautiously optimistic, eyeing further developments that could sustain this upward trajectory in the weeks ahead.

(Word count: 928)

Read the Full The New Zealand Herald Article at:
[ https://www.nzherald.co.nz/business/markets/shares/healthcare-giants-drive-positive-day-on-nz-sharemarket-market-close/KL3C3GHYORFMLHXRJXE3WKGQL4/ ]